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Formononetin promotes 
angiogenesis through the estrogen 
receptor alpha-enhanced ROCK 
pathway
Shang Li1, Yuanye Dang1, Xuelin Zhou2, Bin Huang1, Xiaohui Huang1, Zherui Zhang1, 
Yiu Wa Kwan2, Shun Wan Chan3, George Pak Heng Leung4, Simon Ming Yuen Lee1 & 
Maggie Pui Man Hoi1
Formononetin is an isoflavone that has been shown to display estrogenic properties and induce 
angiogenesis activities. However, the interrelationship between the estrogenic properties and 
angiogenesis activities of formononetin are not well defined. In the present study, docking and 
enzymatic assay demonstrated that formononetin displayed direct binding to the ligand-binding 
domain (LBD) of estrogen receptor alpha (ERα) with an agonistic property. Results from Human 
Umbilical Vein Endothelial Cells (HUVEC) by using real-time migration xCELLigence system, 
immunofluorescence and western blotting provided strong evidences of formononetin induced 
endothelial cell migration and dramatic actin cytoskeleton spatial modification through ERα-
enhanced-ROCK-II/MMP2/9 signaling pathways. In addition, results from co-immunoprecipitation 
suggested formononetin induced cell migration via recruiting of ERα/ROCK-II activated complex 
formation. More interestingly, in zebrafish embryo we observed that formononetin significantly 
promoted angiogenic sproutings in the subintestinal vessels (SIVs) that could be completely 
abolished by ROCK inhibitor. In this study, we elucidated the underlying mechanisms that 
formononetin produced proangiogenesis effects through an ERα-enhanced ROCK-II signaling 
pathways. Results from the present study also expand our knowledge about the enigmatic 
underlying mechanisms of phytoestrogenic compounds in the promotion of angiogenesis in relation 
to ERα and ROCK interaction in endothelial cells and their relationship with actin assembly and cell 
migration.
Many flavonoids have been shown to possess pro-angiogenic properties1–4, but the underlying mecha-
nisms are incompletely understood. A number of studies have shown that formononetin, an isoflavone 
and phytoestrogen that displays pro-angiogenic effects, could promote vascular recovery by regulating 
endothelial cell proliferation and migration at sites of vascular injury5,6. It has been reported that, for-
mononetin in a rat fracture model promoted early fracture healing through stimulating angiogenesis by 
up-regulating VEGF and Flk-15 and formononetin promoted the recovery of the migration and prolifera-
tion of wounded (human umbilical vein endothelial cells) HUVEC via increased levels of growth factors6. 
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Estrogen receptors (ERs) are present in the vascular endothelium and it is observed that estradiol could 
induce angiogenesis through the activation of both long-term (genomic) and rapid (non-genomic) 
ER signaling7–9. While both genomic and non-genomic ER signaling are involved in angiogenesis and 
re-vascularization, it has been observed that exposure to the ER agonist 17β -estradiol (E2) leads to ERα 
membrane translocation and rapidly affect membrane modifications8,9, suggesting fast modifications of 
actin cytoskeleton closely related to the non-genomic actions of ERα 10. The dynamics of actin cytoskel-
eton and stress fiber formation are known to be regulated by the small GTPase protein RhoA11. Its 
major downstream effector, Rho-associated protein kinase (ROCK), plays a crucial role in cytoskeleton 
regulation by phosphorylating the myosin-binding subunit of myosin light chain (MLC) phosphatase, 
thereby inhibiting the myosin phosphatase activity and maintaining MLC in a contractile state12. This 
induces F-actin stress fibers formation and focal adhesions that are essential during cell migration13,14. 
ROCK also activates Lim kinase (LIMK) to inhibit cofilin, which prevents actin depolymerization, and 
further increases contractility by directly phosphorylating MLC15. Increased contractility can disrupt 
cell-cell adhesion and contributes to increased cell migration. There are evidences that E2 enhances 
endothelial cell migration through the Rho/ROCK pathway by acting through the ERs in endothelial 
cells16,17. However, the molecular mechanisms underlying the action of formononetin in ER, and the 
direct relationship with the action of ER and angiogenesis, are yet to be fully elucidated.
Endothelial cell proliferation and migration are essential processes in the development of angiogen-
esis which requires orchestrated movement of cells in particular directions to specific locations, closely 
involving the modification and spatial organization of actin cytoskeleton. Many phytoestrogens are 
shown to have pro-angiogenic effects, but whether phytoestrogens could induce effects on the regulation 
of cytoskeleton is unclear. In this study, we investigated the relationship of the pro-angiogenic actions 
of formononetin with ERα by performing molecular modeling and corresponding cell-based ERα tran-
scriptional response reporter gene assay. The evaluation of formononetin-induced sprouting angiogen-
esis was also evaluated in zebrafish embryo in vivo and the formononetin-induced ROCK signaling in 
cytoskeleton reorganization and endothelial cell migration were evaluated in HUVEC.
Results
Identification of formononetin as a ligand at ERα by molecular docking analysis and cell-
based GeneBLAzer enzymatic assay. It has been reported that formononetin possesses estrogenic 
activity. Therefore, we first studied the interaction between formononetin and the ligand binding pocket 
(LBD) of ERα by molecular docking. In general, ERα ligands form hydrogen bonds with Glu353 and 
Arg394 in the ERα LBD to promote structural stabilization. Figure  1A showed chemical structure of 
formononetin. Figure 1B illustrated that the methoxy group (–OCH3) at 4′ -position of formononetin was 
Figure 1. Formononetin exhibited direct binding and agonistic properties at ERα. (A) The molecular 
structure of formononetin. (B) Three-dimensional structural models of formononetin fitted into the ligand 
binding domain (LBD) of ERα . Formononetin was colored pink. Side chains in ERα LBD are colored by 
atom type (carbon, grey; oxygen, red; hydrogen, blue). (C) In vitro cell-based GeneBLAzer β -lactamase 
reporter-gene assay showed that formononetin induced the transactivation of ERα significantly. (D) 
Formononetin showed minimal inhibitory effects on the ERα transactivation induced by17-β -estradiol (E2). 
Results are presented as mean ± SD (n ≥ 2), p < 0.01.
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able to form hydrogen bonds with the Glu 353 and Arg 394 of ERα LBD, and the carbonyl group (C= O) 
interacted with the Leu 349 of ERα LBD. We furthered investigated the actions of formononetin with 
cell-based GeneBLAzer nuclear receptor activation assay. Figure 1C showed that formononetin exhibited 
agonistic effect and induced the transactivation of ERα significantly. Figure 1D showed that formonone-
tin in high concentration (100 μ M) exhibited minimal inhibitory effects in 17-β -estradiol (E2)-induced 
ERα transactivation in the antagonistic experiment (Fig. 1D).
Formononetin induced endothelial cell migration and stress fiber formation in HUVECs. In 
angiogenesis, endothelial cells proliferation and migration contribute to the dissemination from 
pre-existing vessels to form new vessels. The effects of formononetin on endothelial cells proliferation 
and migration were investigated in human umbilical vein endothelial cells (HUVECs). Cell proliferation 
and cytotoxicity were first evaluated by using the XTT and LDH assays. It was observed that formon-
onetin (12.5, 25, 50 or 100 μ M for 48 h) did not induce HUVECs cell proliferation, and 100 μ M formon-
onetin caused cytotoxicity by inducing significant LDH release (Supplementary Fig. 1). We then further 
investigated the effect of formononetin on cell migration. It was observed that formononetin enhanced 
HUVECs migration following scrape injury (Fig.  2A–C). Quantitative analysis of the real-time migra-
tion of HUVECs in response to formononetin with the xCELLigence system showed that formononetin 
enhanced cell migration in a dose-dependent manner (Fig.  2H). More interestingly, it was found that 
formononetin induced actin cytoskeleton rearrangement in HUVECs and enhanced the formation of 
stress fibers (Fig. 2E,e–G,g). These stress fibers terminated at pointed edges and were typical morpholog-
ical feature in migrating cells. These results indicated that formononetin stimulated HUVECs migration 
by inducing stress fiber formation.
Figure 2. Formononetin induced cell migration and stress fiber formation in HUVECs. Formononetin 
enhanced the migration of HUVECs following scrape injury. (A,B) Serum-starved HUVEC monolayers 
were wounded (0 h) by micro-tips and washed with PBS, followed by addition of (A,a) 0.1% DMSO medium 
or (B,b) 25 μ M formononetin for 8 h. (C) Statistical analysis of cell migration recorded by phase contrast 
microscopy following each scratch. The extent of migration was determined by averaging the mean length 
of the scraped area (gap width) of the migration pattern of endothelial cells. Formononetin also induced 
the rearrangement of actin cytoskeleton in HUVECs. Serum-starved HUVECs were treated with (D,d) 0.1% 
DMSO as control, and formononetin at (E,e) 12.5, (F,f) 25 and (G,g) 50 μ M for 8 h. Cell nuclei were labeled 
with Hochest 33342 and F-actin was labeled with tetramethyl rhodamine isothiocyanate (TRITC)-phalloidin. 
Formononetin increased the formation of stress fibers that terminated at pointed edges (yellow arrowhead) 
and growth lamellipodia (white asterisk). White and yellow scale bars represent 50 and 20 μ m, respectively. 
(H) HUVECs migration in response to different concentrations of formononetin was analyzed using the 
xCELLigence system. Real-time cell migrations of serum-starved HUVECs following the treatment of 12.5, 
25 and 50 μ M formononetin for 24 h were recorded. (I) Statistical analysis of the migration index of the 
xCELLigence system following formononetin treatments for 20 h. 40 ng/ml of VEGF was served as a positive 
control. Values are given as the increment of migration ± SD (n = 3), for three independent experiments. 
**p < 0.01, **p < 0.001 vs. control.
www.nature.com/scientificreports/
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The role of ERα in formononetin-induced endothelial cell migration and stress fiber forma-
tion in HUVECs. Since our molecular docking and enzymatic transactivation assay showed that for-
mononetin exhibited direct binding and agonistic at ERα , we further investigated the role of ERα activity 
in the pro-angiogenic endothelial cell migration induced by formononetin in HUVECs. HUVECs were 
transfected with either non-specific siRNA to serve as negative control (Fig.  3A–D) or with siRNA 
against ERα mRNA (Fig. 3E–H). It was observed that the inhibition of ERα expression in HUVECs sig-
nificantly prevented the increased stress fiber formation induced by formononetin. Figure 3I,G showed 
that the concurrent cell migrations of HUVECs induced by formononetin treatments were also signif-
icantly inhibited by silencing ERα with siRNA. Similarly, the estrogen receptor antagonist ICI 182,780 
significantly reduced the formononetin-induced stress fiber formation and cell migration (Fig. 4).
Formononetin induced stress fiber formation and cell migration in HUVECs through ROCK 
and MMP2/9 signaling pathways. We further investigated the underlying mechanism of the 
formononetin-induced actin cytoskeleton rearrangement in HUVECs. Previous studies have demon-
strated that the activation of ROCK signaling pathway is closely related to the regulation of stress fiber 
formation and cell migration in endothelial cells13,14. Figure 5B,b showed that HUVECs transfected with 
non-specific siRNA when treated with formononetin (50 μ M), actin stress fiber formation was increased 
significantly and the fibers were arranged longitudinally through the major axis of the endothelial cells. 
When HUVECs were transfected with ROCK-II siRNA, there was a reduction in actin stress fiber as 
well as a rapid modification of the stress fiber spatial organization with a progressive localization of actin 
towards the edge of the cell membrane to form cortical actin complexes (Fig. 5C,c). More interestingly, 
Figure 3. Inhibition of ERα expression by ERα siRNA abolished formononetin-induced stress fiber 
formation and cell migration in HUVECs. HUVECs were transfected with non-specific siRNA for 2 days 
followed by (A) 0.1% DMSO, (B) 12.5, (C) 25 and (D) 50 μ M formononetin for 8 h to serve as negative 
control. HUVECs were transfected with ERα siRNA for 2 days followed by (E) 0.1% DMSO, (F) 12.5,  
(G) 25 and (H) 50 μ M formononetin for 8 h. Cell nuclei were labeled with Hochest 33342 and F-actin was 
labeled with TRITC-phalloidin. Yellow arrowhead indicated stress fibers terminated at pointed edges.  
(I) Real-time cell migration of HUVECs transfected with ERα siRNA with or without formononetin 
treatments as detected by the xCELLigence system. HUVECs were transfected with non-specific siRNA or 
ERα siRNA for 2 days followed by 0.1% DMSO, 12.5, 25 or 50 μ M formononetin for 24 h. (G) Statistical 
analysis of cell migration of HUVECs transfected with ERα siRNA following formononetin treatment for 20 h. 
Results are expressed as percentages of controls in mean ± SD (n = 3), **p < 0.01, ***p < 0.001 vs. control.
www.nature.com/scientificreports/
5Scientific RepoRts | 5:16815 | DOI: 10.1038/srep16815
the inhibition of ROCK-II expression by siRNA abolished the actions of formononetin to increase stress 
fiber formation (Fig. 5D,d) as well as cell migration (Fig. 5E,F). Moreover, the cell migration of wounded 
HUVECs induced by formononetin treatment following scrape injury was completely abolished by the 
transfections of either ERα siRNA or ROCK-II siRNA (Supplementary Fig. 2). The effects of formonone-
tin on the regulations of the downstream effectors of ROCK activation were further evaluated by using 
western blotting. The downstream substrates of ROCK proteins including MMP2/9 (matrix metallo-
proteinase 2/9), MYPT1 (myosin phosphatase target subunit 1), LIMK1 (Lim kinase 1), MLC2 (myosin 
light chain 2) and cofilin have been shown to regulate cell migration. Our data showed that formon-
onetin increased the expressions of MMP2 and MMP9 in HUVECs significantly in a time-dependent 
manner (Fig. 6A,B). Formononetin also concurrently increased the phosphorylation of MYPT1, MLC2, 
LIMK1 and cofilin as shown in Fig. 6A,C. These effects induced by formononetin were abolished by the 
transfection of ROCK-II siRNA in HUVECs. Figure 7 showed that the transfection of ROCK-II siRNA 
resulted in marked reduction in the expression of ROCK-II protein along with similar decrease in the 
phosphorylation of MYPT1, MLC2, LIMK1, cofilin and the expression of MPP2 and MPP9 in formon-
onetin treated HUVECs (Fig. 7).
Figure 4. Blockade of ERα activity by ER antagonist ICI 182,780 abolished formononetin-induced 
stress fiber formation and cell migration in HUVECs. HUVECs were treated with (A,a) 0.1% DMSO 
for 8 h as negative control and (B,b) 50 μ M formononetin for 8 h as positive control. For the experiments 
with ICI 182,780, HUVECs were first treated with ICI 182,780 (10 μ M) for 2 h, followed by washout and 
the treatments of (C,c) 0.1% DMSO, and (D,d) 50 μ M formononetin for 8 h. Cell nuclei were labeled with 
Hochest 33342 and F-actin was labeled with TRITC-phalloidin. Yellow arrowhead indicated stress fibers 
terminated at pointed edges. Cortical actin complexes (white arrowhead) were formed in the ICI 182,780 
treatment group. (E) Real-time cell migration of HUVECs by using the xCELLigence system showed that 
ICI 182,780 inhibited formononetin-induced cell migration. HUVECs were treated with ICI 182,780 (10 μ M) 
for 2 h, followed by washout and treatment with 0.1% DMSO or 50 μ M formononetin for 24 h. (F) Statistical 
analysis of HUVECs cell migration following formononetin treatment for 20 h. Results are expressed as 
percentages of controls (means ± SD; n = 3), **p < 0.01, ***p < 0.001 vs. control.
www.nature.com/scientificreports/
6Scientific RepoRts | 5:16815 | DOI: 10.1038/srep16815
The role of ERα in the activation of ROCK and MMP2/9 pathways in formononetin-induced 
stress fiber formation and cell migration in HUVECs. The role of ERα in the activation of ROCK 
and MMP2/9 pathways by formononetin was further evaluated by using ERα siRNA. Figure 8 showed 
that HUVECs transfected with ERα siRNA resulted in a marked reduction in ERα expression along 
with marked reductions in the protein levels of MMP2 and MMP9, and the phosphorylation of MYPT1, 
LIMK1, cofilin and MLC2 upon exposure to formononetin. To further characterize the signaling part-
nership between ERα and ROCK, co-immunoprecipitation assays were performed. It was observed that 
in the presence of formononetin, there was significant increased in the interaction between ERα and 
ROCK-II (Fig. 9A–D). In order to dissect the functional relevance of the ERα /ROCK-II interaction, we 
further investigated if the ERα -associated ROCK-II is functionally activated by using the ER antagonist 
ICI 182,780. It was observed that the treatment of ICI 182,780 disrupted the interaction between ERα /
ROCK-II induced by formononetin (Fig.  9E–H). These results suggested that formononetin induced 
direct association of ERα with ROCK-II that further led to the formation of an activated multi-protein 
complex.
Formononetin induced angiogenic sprouting in subintestinal vessels (SIVs) in zebrafish in 
vivo. In order to determine if formononetin exerted pro-angiogenic effects in vivo, we employed the 
Figure 5. Inhibition of ROCK-II expression by ROCK-II siRNA abolished formononetin-induced 
stress fiber formation and cell migration in HUVECs. HUVECs transfected with non-specific siRNA 
were treated with (A,a) 0.1% DMSO or (B,b) 50 μ M formononetin for 8 h to serve as negative and positive 
control, respectively. Cell nuclei were labeled with Hochest 33342 and F-actin was labeled with TRITC-
phalloidin. Yellow arrowhead indicated stress fibers terminated at pointed edges. ROCK-II expression 
was inhibited in HUVECs by using ROCK-II siRNA and the cells were treated with (C,c) 0.1% DMSO or 
(D,d) 50 μ M formononetin for 8 h. White asterisk indicated cortical actin complexes formed in HUVECs 
transfected with ROCK-II siRNA. White and yellow scale bars represent 50 μ m and 20 μ m respectively. 
(E) Real-time cell migration of HUVECs transfected with ROCK-II siRNA with or without formononetin 
treatments as detected by the xCELLigence system. HUVECs were transfected with ROCK-II siRNA for 
2 days, followed by 0.1% DMSO or 50 μ M formononetin for 24 h. (F) Statistical analysis of cell migration 
index of xCELLigence system following formononetin treatment for 20 h. Values are presented as the 
increment of migration ± SD (n = 3), for three independent experiments. **p < 0.01 vs. control.
www.nature.com/scientificreports/
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transgenic zebrafish models Tg (fli1: EGFP)y1 and Tg (fli1: nEGFP)y7. Tg (fli1: EGFP)y1 zebrafish were 
engineered to express green fluorescent protein (GFP) in the entire vasculature and Tg (fli1: nEGFP)y7 
harbored nuclear-localized GFP expression in the endothelial cells permitting real time in vivo analy-
sis of individual endothelial cells. Figure  10A showed that under normal condition, zebrafish embryos 
developed a smooth, basket-like structure in the region of the subintestinal vessels (SIVs) at 72 hour post 
fertilization (hpf). The treatments of formononetin at 25 μ M (Fig. 10B,b) or 50 μ M (Fig. 10C,c) increased 
Figure 6. Formononetin induced the activation of ROCK and MMP2/9 signaling pathways in HUVECs. 
HUVECs were treated with 50 μ M formononetin for 15, 30, 45, 60 min. Cells were subsequently harvested 
and extracted for western blot analysis. (A) The protein expression of the ROCK signal pathway and 
MMP2/9 were determined by western blotting. β -actin was used as a loading control. (B,C) Results are 
expressed as a percentage of controls (mean ± SD; n = 3), *p < 0.05, **p < 0.01 vs. control.
Figure 7. Inhibition of ROCK-II expression by ROCK-II siRNA abolished the activation of ROCK and 
MMP2/9 signaling pathways in HUVECs. (A) HUVECs were transfected with either non-specific siRNA as 
control or specific ROCK-II siRNA for 2 days followed by 50 μ M formononetin treatment for 30 or 60 min. 
The protein levels of ROCK-II, MMP2, MMP9, P-MYPT1, P-LIMK1, P-cofilin and P-MLC2 were analyzed 
by using Western blotting. (B) Statistical analysis of the protein levels of MMP2 and MMP9 in HUVECs 
transfected with ROCK-II siRNA in the presence of 50 μ M formononetin. (C) Statistical analysis of the 
protein levels of P-MYPT1, P-LIMK1, P-cofilin and P-MLC2 in HUVECs transfected with ROCK-II siRNA 
in the presence of 50 μ M formononetin. Results are expressed as a percentage of control (means ± SD, 
n = 3), *p < 0.05, **p < 0.01 vs. control.
www.nature.com/scientificreports/
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Figure 8. Formononetin induced the activations of ROCK and MMP2/9 pathways via ERα. (A) 
HUVECs were transfected with either non-specific siRNA as control of specific ERα siRNA for 2 days 
followed by 50 μ M formononetin treatment for 30 or 60 min. The protein levels of ERα , MMP2, MMP9, 
P-MYPT1, P-LIMK1, P-cofilin and P-MLC2 were analyzed by using Western blotting. (B) Statistical analysis 
of the protein levels of MMP2 and MMP9 in HUVECs transfected with ERα siRNA in the presence of 
50 μ M formononetin. (C) Statistical analysis of the protein levels of P-MYPT1, P-LIMK1, P-cofilin and 
P-MLC2 in HUVECs transfected with ERα siRNA in the presence of 50 μ M formononetin. Results are 
expressed as percentages of controls (mean ± SD; n = 3), *p < 0.05, **p < 0.01 vs. control.
Figure 9. Inhibition of ER activation by ICI 182,780 abolished the interaction between ERα 
and ROCK-II induced by formononetin. (A–D) HUVECs were treated with 0.1% DMSO or 50 μ M 
formononetin for 15, 30, 45 and 60 min. (E–H) HUVECs were pretreated with 10 μ M ICI 182,780 for 2 h, 
followed by washout and treatment with 0.1% DMSO or 50 μ M formononetin for 30 and 60 min. HUVECs 
protein extracts were immunoprecipitated with anti-ERα antibody and the immunoprecipitations (IPs) 
were assayed for co-immunoprecipitation of ROCK-II with Western blotting. HUVECs total protein was 
directly assayed with western blotting analysis as controls. Results are expressed as percentage of control in 
mean ± (n = 3), *p < 0.05, **p < 0.01 vs. control.
www.nature.com/scientificreports/
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the sprouting in the SIVs in a dose-dependent manner. The increase in sprouts formation induced by 
formononetin was similar to the effect of zebrafish VEGF-A (ZF-VEGF-A) (1 ng/embryo) (Fig. 10D,d). 
We further evaluated the phenotype and the behavior of individual endothelial cells to determine if 
the pro-angiogenic effects of formononetin were caused by endothelial cell proliferation and migration. 
Quantitative analysis indicated that formononetin (50 μ M) significantly induced an increase in the length 
of sprouting vessels (Fig. 10E) as well as a slightly increase in the endothelial cell populations throughout 
the region of the SIVs (Fig. 10F), similar to the effects induced by ZF-VEGF-A injection.
The bars chart in Fig. 11J represent the gene expression of angiogenesis factors after treatment with 
50 μ M formononetin for 6 h. There was a significant increase of the mRNA expressions of VEGF-A 
(1.6-fold at 50 μ M; p < 0.01) and Flt1 (or VEGFR1) (1.25-fold at 50 μ M; p < 0.05) but not Kdr (or 
VEGFR2) (1.18-fold at 50 μ M; p > 0.05) compared to the control.
Formononetin induced angiogenic sproutings in the SIVs of zebrafish embryos in vivo 
through multiple signaling pathways with ROCK contributing a key role. We further inves-
tigated the role of estrogen receptors (ER) in the pro-angiogenic sproutings induced by formononetin 
in zebrafish embryos by using the ER antagonist ICI 182,780. Figure  11A showed that under normal 
condition. Figure  11B showed the treatment of formononetin at 50 μ M increased the sprouting in the 
SIVs. Figure 11C showed the treatment of ICI 182,780 no significantly changed the morphology of SIVs. 
Figure 11D showed that in the presence of ICI 182,780 (50 μ M), the formononetin-induced sproutings in 
the SIVs were partially inhibited. The statistical analysis in Fig. 11I showed that this inhibition induced 
Figure 10. The effects of formononetin on angiogenic sprouting in the SIVs of Tg (fli1: EGFP)y1 
and Tg (fli1: nEGFP)y7 zebrafish embryos. (A,a) Tg (fli1: EGFP)y1 and Tg (fli1: nEGFP)y7 zebrafish 
embryos (48 hpf) were treated with 0.1% DMSO for 24 h to serve as negative control. The SIVs of zebrafish 
embryos at 72 hpf developed into a smooth basket-like structure. Zebrafish embryos (48 hpf) treated with 
formononetin for 24 h at (B,b) 25 μ M or (C,c) 50 μ M showed that there was an increase of sprouting in the 
subintestinal vessels (SIVs) baskets stretching into the posterior yolk extension. (D,d) Zebrafish embryos 
were injected with zebrafish VEGF-A (ZF-VEGF-A) (1 ng/embryo) at 1 hpf and incubated in embryo 
medium until 72 hpf to serve as positive control. Yellow arrows indicated sprouting vessel formation; white 
asterisks indicated intersection branch formation. Statistical analysis showed that formononetin increased  
(E) the length of vascular sprouting in the SIVs and (F) the number of endothelial cells in the SIVs in a 
dose-dependent manner. The number of endothelial cells was measured using Image J software package. 
Data are plotted as mean ± SD, (n > 3), *p < 0.05, **p < 0.01 vs. control.
www.nature.com/scientificreports/
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by ICI 182,780 was modest but significant. In addition, it was also observed that ICI 182,780 was unable 
to reduce the up-regulation of VEGF-A expression stimulated by formononetin treatment in zebraf-
ish embryos (data not shown). Previous studies have demonstrated that VEGF-A morphant zebrafish 
embryos failed to develop complete vasculature with complete absence of the intersegmental and axial 
vasculature18. In the present study, we also observed that VEGF-A morphant embryos (72 hpf) failed 
to develop the SIVs (subintestinal vessels) (Fig. 11E,H), and that the angiogenic sproutings induced by 
formononetin were abolished by the injection of VEGF-A morpholino (VEGF-A MO) (Fig. 11F).
We further investigated the role of the ROCK pathway in formononetin-induced sproutings in vivo 
in zebrafish by using the ROCK inhibitior H1152. In agreement with the results in HUVECs, H1152 
abolished the sproutings induced by formononetin significantly (Fig.  12D–F). These results suggested 
that formononetin induced angiogenesis in zebrafish embryos via multiple pathways and various steps 
in angiogenesis (e.g. cell proliferation and migration).
Discussion
Angiogenesis is not only a prerequisite for physiological tissue development and regeneration, but also 
an integral part of chronic disease pathogenesis. Therefore, it is not surprising that therapies targeting 
angiogenesis have been sought from both perspectives. Pro-angiogenic therapies have been investigated 
for treating ischemic heart disease, wound healing, and other disease settings with an impaired blood 
supply19,20. On the contrary, in cancer, diabetic retinopathy, rheumatoid arthritis and other diseases 
where neovascularization is a problem, efforts have been made to develop therapies that inhibit angio-
genesis21,22. In the present study, we investigated the underlying mechanisms of the angiogenic effects 
induced by formononetin. Formononetin is an isoflavone that has been shown to display estrogenic 
Figure 11. The effects of ICI 182,780 (ER antagonist) and vegfa morpholino on formononetin-induced 
angiogenesis in zebrafish embryos in vivo. Tg (fli1: EGFP)y1 zebrafish embryos (48 hpf) were treated with 
(A) 0.1% DMSO (negative control), (B) formononetin (50 μ M) (positive control), (C) co-treatment of ICI 
182,780 (50 μ M) and formononetin (50 μ M), (D) ICI 182, 780 (50 μ M) alone. All treatments were for 24 h. 
Tg (fli1: EGFP)y1 zebrafish embryos (1 hpf) were injected with (E) Vegfa MO (2 ng) alone and (F) Vegfa MO 
(2 ng) injection + formononetin treatment (50 μ M, at 48 hpf for 24 h) and were observed at 72 hpf.  
(G,H) Control images of zebrafish embryos at 1–4 cells stage and 24 hpf after Vegfa MO injection. (I) Data 
were analyzed by using the Image J software package. Quantitative analysis indicated the total length of 
SIVs for each group. (J) Evaluation of gene expressions in formononetin-treated zebrafish embryos by using 
real-time PCR. Data are plotted as means ± SD from three individual experiments. *p < 0.05, **p < 0.01 vs. 
control group.
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properties23,24. Formononetin is also an active ingredient in Radix Astragali, a Chinese medical herb that 
promotes hind limb ischemia-induced wound healing in diabetic rats by promoting angiogenesis25–27. 
Here we showed for the first time that formononetin displayed direct binding to the LBD (ligand bind-
ing domain) of ERα (estrogen receptor alpha) by using molecular docking. Moreover, the data from the 
cell-based GeneBLAzer assays which evaluated the transactivation of ERα showed that formononetin 
demonstrated agonistic activity at ERα . It is now known that ERα are expressed in endothelial cells, 
and ERα agonists could induce endothelial cell proliferation and migration, and mediate angiogenesis7,28.
It has been reported that formononetin promoted tissue healing in early fracture through stimulat-
ing angiogenesis by up-regulating growth factors including VEGF and Flk-1 in a rat fracture model5. 
In another report, formononetin was observed to induce endothelial cell proliferation and migration 
of wounded HUVECs by significantly increasing growth factors6. In line with this, our in vivo data in 
zebrafish embryos showed that the gene expressions of VEGF-A and Flt1 were significantly up-regulated 
by formononetin treatment, and the injection of vegfa morpholino disrupted the normal vasculature 
development in zebrafish embryos and the addition of formononetin was unable to produce any angio-
genesis in the VEGF-A morphant. These results indicated that formononetin promoted angiogenesis to 
induce sprouting formation in zebrafish. Moreover, the proangiogenesis activities of formononetin are 
also through VEGF signaling pathway. However, angiogenesis is a multi steps process with endothelial 
cell proliferation, migration and capillary network formation as the fundamental procedures. Therefore, 
we further elucidated the underlying mechanisms of formononetin-induced pro-angiogenic effects on 
the endothelial cells by using HUVECs. In the present study, we observed for the first time that for-
mononetin induced endothelial cell migrations and dramatic actin stress fiber formation and spatial 
modification of the actin cytoskeleton in endothelial cells. Moreover, formononetin did not induce 
Figure 12. The effects of ROCK inhibitor in formononetin-induced angiogenesis in zebrafish embryos 
in vivo. Tg (fli1: EGFP)y1 zebrafish embryos (48 hpf) were treated with (A) 0.1% DMSO (negative control), 
(B) formononetin (25 μ M), (C) formononetin (50 μ M), (D) H1152 (10 μ M, ROCK inhibitor) alone, (E) co-
treatment of H1152 (10 μ M) + formononetin (25 μ M), (F) co-treatment of H1152 (10 μ M) + formononetin 
(50 μ M). All treatments were for 24 h. (G) Quantitative analysis indicated the length of sprouting in SIVs for 
each group. Data are plotted as means ± SD, from three individual experiments. *p < 0.05, ***p < 0.001 vs. 
control group.
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any significant increase in endothelial proliferation. Formononetin induced the rearrangement of actin 
cytoskeleton into the migratory phenotype (stress fibers terminated at pointed edges and concentrated 
at growth lamellipodia). Further investigation by using ICI 182,780 (estrogen receptors antagonist) and 
anti-ERα siRNA showed that ERα activation contributed significantly to the formononetin-induced 
cell migration and stress fiber formation. These effects were associated with an increase in matrix met-
alloproteinase MMP2/9 expressions and the activation of the ROCK (Rho-associated protein kinase) 
signaling pathway. It has been reported that MMP2 and MMP9 are predominately expressed in the 
endothelial cells and are directly involved in endothelial cell migration and vascular remodeling during 
angiogenesis29. ROCK is a major downstream effector of RhoA, and contributes to stress fiber formation 
by inactivating myosin phosphatase and by phosphorylating myosin light chain. ROCK also activates 
Lim kinase (LIMK) to phosphorylate and thereby inhibiting cofilin to prevents actin depolymerization. 
Increased actin depolymerization and myosin contractility resulted in F-actin stress fibers formation and 
tension that play essential roles in cell migration13,14. Results from this study showed that formononetin 
increased protein expression of MMP2/9 and ROCK-II, and enhanced the phosphorylation of its major 
downstream effectors and substrates including MYPT1 (myosin phosphatase target subunit 1), LIMK1 
(Lim kinase 1), MLC2 (myosin light chain 2) and cofilin. The increased in MMP2/9 and the enhanced 
phosphorylation of MYPT1, LIMK1, MLC2 and cofilin were all inhibited by the anti-ROCK-II siRNA. 
The results provided strong evidence that ROCK signaling pathway is a major mechanism underlying 
the pro-angiogenic cell migration induced by formononetin. In addition, in agreement with the results 
above that anti-ERα siRNA inhibited formononetin-induced stress fiber formation and cell migration, 
anti-ERα siRNA or ICI 182,780 also inhibited the formononetin-induced MMP2/9 expression and 
ROCK signaling activation. Indeed, “non-genomic” effects of estrogens has been reported which acts on 
endothelial cell to modify actin cytoskeleton arrangement and endothelial cell migration via the activa-
tion of surface ERα , recruiting RhoA/ROCK-II/moesin cascade16,30. We further provided more evidence 
of the interaction between ERα and ROCK-II by using co-immunoprecipitation, and the ERα /ROCK-II 
interaction was disrupted by ICI 182,780. To further investigate formononetin-induced the activation of 
ROCK signaling pathway may also be related the interactions of formononetin to factors other than ERα , 
we then applied docking analysis to simulate the interaction between formononetin and upstream factors 
of ROCK signaling, such as VEGFR2, TGF-beta receptor 1, or RhoA (Supplementary Fig. 3). Through 
the docking analysis, formononetin strongly bound to LBD of ERα , very weakly bound the kinase activa-
tion site of VEGFR2 and TGF-beta receptor 1, but did not bind to RhoA (Supplementary Table 1). These 
results further confirmed that formononetin induced the activation of ROCK signaling pathway via the 
interaction with ERα . Interestingly, previous study showed that formononetin in high concentrations 
(> 50 μ M) acted as a strong pro-apoptotic agent inducing antiangiogenesis in cancer cell lines31,32. In line 
with previous study, we found that formononetin in high concentrations (> 50 μ M) could also induce cell 
death in HUVECs (Supplementary Fig. 1). Overall, according to previous study and our current results, 
we assume that formononetin in low concentrations (< 50 μ M) have proangiogenesis effects while in high 
concentrations (> 50 μ M) display anti-angiogenesis effects. These results support formononetin can be 
used in the treatment of insufficient and sufficient angiogenesis diseases such as ischemic heart disease, 
wound healing and metastatic cancers.
Taken together, these results lead us to postulate that formononetin induced endothelial cell migra-
tion and stress fiber formation and promoted angiogenesis through an ERα -enhanced ROCK pathway by 
forming an ERα /ROCK-II activated complex (Fig. 13). These results expand our knowledge pertaining 
to the basis of the effects of phytoestrogens in angiogenesis, including the regulation of ERα and ROCK 
interaction relevant to actin assembly and cell migration. This new concept might provide support for the 
pro-angiogenic activities of formononetin and other phytoestrogens during the treatment of conditions 
related to vascular insufficiency, such as wound healing and diabetic vascular complications.
Methods
Ethical Statement. The experiments in this manuscript comply with the current laws of Macau. 
All the animal experiments in this manuscript were conducted according to the ethical guidelines of 
the Institute of Chinese Medical Sciences (ICMS), University of Macau. The protocol was approved by 
the Institute of Chinese Medical Sciences—Animal Ethics Committee (ICMS-AEC; Permit Number: 
20120601). All experiments were performed in accordance with relevant guidelines and regulations.
Chemicals and reagents. Human Umbilical Vein Endothelial Cells (HUVEC) were obtained 
from Thermo Fisher Scientific Inc. (NYSE: TMO), maintained in Vascular Cell Basal Medium ATCC 
(Manassas, VA), and used prior to passage 7. Fetal bovine serum (FBS), phosphate-buffered saline (PBS), 
penicillin-streptomycin (PS) and 0.25% (w/v) trypsin/1 mM EDTA were all purchased from Invitrogen 
(Carlsbad, CA, USA). Endothelial cell growth supplement (ECGS), heparin and gelatin were all sup-
plied by Sigma (St Louis, MO). Vascular endothelial growth factors (VEGF) were obtained from R&D 
Systems (Minneapolis, MN). Anti-MMP2/9 antibody, Anti-ROCK-II antibody, anti-MYPT1 antibody, 
Anti-LIMK1 antibody, Anti-cofilin antibody, Anti-MLC2 antibody, Anti-β -actin antibody and goat 
anti-rabbit IgG HRP-conjugated antibody were all purchased from Cell Signaling Technology (Berverly, 
MA). Anti-ERα Antibody was purchased from Santa Cruz Biotechnology, Inc. Dimethyl sulfoxide 
(DMSO) was acquired from SIGMA. Formononetin was obtained from the Chinese National Institute 
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for Control of Pharmaceutical and Biological Products (Beijing, China) and was dissolved in DMSO to 
form a 50 mM solution.
Molecular docking study. Molecular docking analysis was performed to investigate the binding of 
formononetin to human estrogen receptor alpha (ERα ) (PDB code 2QZO) which were obtained from 
the Protein Data Bank. The software AutoDcok Vina ver. 4.2 was used for all dockings33,34. A Lamarckian 
genetic algorithm (LGA) was used to search for conformations using the following docking parame-
ters: a population size of 150 individuals; a maximum number of generations and energy evaluations 
of 27000 and 25 million, respectively; and 50 docking runs and random initial positions and confor-
mations. The binding energy of each conformation was calculated using the AMBER force field, and a 
root mean squared deviation (R.M.S.D) tolerance of 0.7 Å was used to cluster the conformations using 
the AutoDock Tools software package. The lowest energy, and highest cluster conformations, of two 
molecules were further analyzed and compared using the Discovery Studio software package (Accelrys).
Zebrafish embryo preparation and drug treatments. All animal experiments were undertaken 
following the approved protocol of Institute of Chinese Medical Sciences of the University of Macau. 
Zebrafish embryo preparation proceeded as described in our previous paper3. Transgenic Tg (fli1: EGFP)
y1 and Tg (fli1: nEGFP)y7 zebrafish were maintained separately under a 14 h light/10 h dark cycle and 
standard conditions. Embryos were generated by pairwise mating (of fish between 3 and 12 months 
of age) and incubated at 28.5 °C in embryo medium. Only embryos aged 48 h post-fertilization (hpf) 
were used in the experiments. For morphological analysis, 12.5, 25, 50 and 100 μ M formononetin were 
dissolved directly in 2 ml MilliQ water, in a twelve-well microplate, with 15 individual embryos in each 
treatment group. The vehicle control group was treated under the same conditions, but drug was replaced 
with 0.1% DMSO. All groups were incubated at 28 °C for 24 h.
Morphological observation of zebrafish. At 96 hpf, embryos taken from microplates were 
observed for viability and gross morphological changes under a fluorescence microscope (Olympus IX81 
Motorized Inverted Microscope, Japan) equipped with a digital camera (DP controller, Soft Imaging 
System, Olympus). For the assessment of vascular changes, images were analyzed using Axiovision 4.2 
and Adobe Photoshop 7.0, to quantify vascular changes. The quantitative analysis of the SIVs of Tg (fli1: 
Figure 13. Formononetin induced pro-angiogenic actin stress fiber formation and cell migration in 
endothelial cells involving ERα/ROCKII signaling pathways as major regulators. 
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EGFP)y1 zebrafish embryo were chosen for the measurement of total vessels or sprouting vessels length 
in SIVs, using the AxiovisionLE software package (ver. 4.1) and Image J.
Morpholino and VEGF-A injections. Morpholino antisense oligonucleotides were purchased 
from Gene-Tools, LLC (Philomath, OR). A 1 nl volume of 2 mM morpholino or control morpholino 
(Gene-Tools, Philomath, OR), was injected into transgenic Tg (fli-1: EGFP)y1 embryos (approximately 
2 ng Vegfa MO) at the 1- to 4-cell stage. The sequence of the injected translation-blocking target mor-
pholino was as follows: Vegfa (NM_001044855.2) 5′ -GGAGCACGCGAACAGCAAAGTTCAT-3′ . 
Zebrafish VEGF-A (1247—ZV- 010, R&D Systems) injection has been described elsewhere35. Briefly, 
we injected approximately 10–15 nl of solution (approximately 1.0–1.5 ng VEGF-A, or PBS as control) 
into either AB or transgenic Tg (fli-1: EGFP)y1 and Tg (fli-1:n EGFP)y7 embryo yolks at the 1- to 4-cell 
stage. All injected embryos were photographed live under a fluorescence microscope (Olympus IX81 
Motorized Inverted Microscope, Japan) using an Olympus DP controller, and the Soft Imaging System 
software package.
Cell-based ER transcriptional response by GeneBLAzer nuclear receptor activation 
assay. Assays were performed by Invitrogen (USA) as described in the literature3. GeneBLAzer 
β -lactamase reporter-gene assays were performed to measure the agonistic or antagonistic activi-
ties of formononetin at ER, the methods for which were described in our previous paper3. For the 
ER agonist activity assay, 17-β -estratiol served as the control agonist. For the antagonist activity assay, 
4-hydroxytamoxifen (starting concentration of 100 nM) for ERα served as the control antagonist. 80% 
effective concentration (EC80) of 17-β -estradiol (E2) was determined and used as the baseline measure 
of activation or 0% inhibition.
Quantitative real time PCR (qRT-PCR). Total RNA extraction, reverse transcription, and real-time 
PCR of zebrafish embryos, at 48 hpf, were treated with 12.5, 25 and 50 μ M formononetin for 6 h. Total RNA 
was extracted from 30 zebrafish embryos of each treatment group using the RNeasy Mini Kit (Qiagen, USA) 
in accordance with the manufacturer’s instructions. RNA was reverse-transcribed to single-strand cDNA 
using the SuperScriptTM III First- Strand Synthesis System for RT-PCR (InvitrogenTM, USA), followed by 
real-time PCR using TaqManH Universal PCR Master Mix and 250 nM custom TaqMan primers for zebraf-
ish Kdr, Flt1, and VEGF-A (Applied Biosystems, USA), in the ABI 7500 Real-Time PCR System (Applied 
Biosystems). The expression of Kdr, Flt1, and VEGF-A mRNA was normalized to the amount of bactin1, 
using the relative quantification method described by the manufacturer. The zebrafish beta-actin1 prim-
ers were 5′ -CATCGGCAATGAGCGTTTCC-3′ (F) and 5′ -CAAGATTCCATACCCAGGAAGG A-3′ (R) 
(Applied Biosystems, USA). The zebrafish Kdr primers were 5′ -CAAGTAACTCGTTTTCTCAACCTAAGC
-3′ (F) and 5′ -GGTCTGCTACACAAC GCATTATAAC-3′ (R) (Applied Biosystems, USA). The zebraf-
ish Flt1 primers were 5′ -AACTCACAGACCAGTGAACAAGATC-3′ (F) and 5′ -GCCCTGTAACGTG 
TGCACTAAA-3′ (R) (Applied Biosystems, USA). The zebrafish VEGF-A primers were 
5′ -GATGTGATTCCCTTCATGGATGTGT-3′ (F) and 5′ -GGATACTCC TGGATGATGTCTACCA-3′ 
(R) (Applied Biosystems, USA). Data analyses were obtained from at least three independent experiments.
HUVEC culture. Human Umbilical Vein Endothelial Cells (HUVEC) were obtained from Thermo 
Fisher Scientific Inc. (NYSE: TMO), and maintained in Vascular Cell Basal Medium ATCC (Manassas, 
VA) at 37 °C in a humidified atmosphere of 5% CO2. Tissue culture flasks, 96-well plates and 6- well 
plates were pre-coated with 2 μ g/cm2 fibronectin. Cultures were then starved with low-serum medium 
(containing 0.5% CS-FBS) overnight in cell viability, toxicity and migration assays. All assays were con-
ducted using low cell passage cells (2–6 passages).
HUVEC viability by XTT assay. HUVECs were trypsinized and seeded at 104 cells/well, in 96-well 
gelatin coated plates. After 24 h, complete medium was removed and renewed with hormone-free low 
serum (0.5% CS-FBS) medium. Samples were then incubated for 24 h, to starve HUVECs and achieve 
a quiescent state. Following these pre-incubations, different concentrations (12.5 μ M–100 μ M) of for-
mononetin medium were replaced. Cells receiving DMSO (0.1%) served as vehicle controls, and were 
equivalent to no treatment. After 24 or 48 h, cell proliferation was assessed by XTT for 4 h. The spectro-
photometrical absorbance of each well was measured by a Multilabel counter (Perkin Elmer, Singapore). 
The wavelength used to measure absorbance of the formazan product was 490 nm. The reference wave-
length was 690 nm. Cell viability data were expressed as a percentage of calculated cell viability.
Lactate dehydrogenase (LDH) assay. HUVEC were grown to 80% confluency on 96 wells plate, 
and were then treated with 12.5, 25, 50 and 100 μ M formononetin for 24 h. Cellular toxicity was deter-
mined by measuring the activity of LDH released into the incubation medium. Released LDH activity was 
determined by the cytotoxicity detection kit according to the manufacturer’s instructions. Absorbance 
was measured using a microplate reader at 490 nm.
Gene silencing with RNA interference. The synthetic siRNA targeting ERα (sc-29305, Santa Cruz 
Biotechnology) and ROCK-II siRNA (h) (sc-29474, Santa Cruz Biotechnology) were used at the final 
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concentration of 100 nM to silence ERα and ROCK-II, with Lipofectamine® LTX & Plus Reagent (15338-
100, Life Technologies Corporation) according to the manufacturer’s instructions. Endothelial cells were 
incubated in complete medium for 48 h following siRNA transfection. The efficacy of gene silencing was 
checked with western blot analysis and discovered to be optimal at 48 h.
Cytoskeleton staining. HUVEC were seeded onto fibronectin-pretreated sterile coverslips placed 
into 96-well plates, and exposed to formononetin for 8 h. Cells were then washed, fixed, permeabilized 
and stained with rhodamine-labelled phalloidin for actin filaments according to a commercial protocol 
(Molecular probe). Cells were observed under a fluorescence microscopy, equipped with a high content 
analysis (HCA) and high content screening (HCS), by an IN Cell Analyzer 2000 (GE Healthcare; excita-
tion at 495 nm, and emission at 520 nm).
Endothelial cell migration assays. Endothelial cell migration was assayed with scrape assays. 
Briefly, ERα or ROCK-II siRNA of endothelial cells were transferred in 12 well plates for 48 h and 
synchronized by replacing the medium with human endothelial serum-free medium (ATCC), devoid 
of growth factors for 12 h. The HUVEC were then scraped away horizontally in each well using a P100 
pipette tip. Three randomly-selected views along the scraped line were photographed on each well using 
phase-contrast microscopy. The media was immediately replaced with fresh media in the presence or 
absence of formononetin. Following 16 h of incubation, a second set of images was photographed. To 
determine whether HUVEC had migrated, the images were analyzed using the Metamorph Imaging 
Series software package. The mean length of the scraped area in each condition was measured and 
deducted from the value obtained prior to treatment. The change in length of the experimental condition 
was compared with that of the control (0.1% DMSO). A decrease in the mean length of the scraped area 
indicated that HUVEC had migrated.
Cell real-time migration assay. Real-time monitoring of endothelial cell migration was per-
formed using the xCELLigence system with the CIM-Plate 16 (Roche). The upper chamber was coated 
with 20 μ g/ml Fibronectin (BD Biosciences) and seeded with ERα or ROCK-II siRNA-transfected at 
50,000 HUVECs. When cells migrated through the membrane into the bottom chamber in response 
to attractants, they contacted and adhered to the electronic sensors, resulting in increased impedance. 
The cell-index values reflecting impedance changes were automatically and continuously recorded every 
15 min.
Immunoblotting. HUVECs were treated with 50 μ M formononetin for different time durations 
(between 5 and 60 min) during the time course study. Medium with 0.1% DMSO served as a vehicle 
control. For inhibition assays, HUVECs were pretreated with 10 μ M ICI182, 780 for 60 min prior to the 
addition of 50 μ M formononetin. Cells were then washed with PBS and lysed for 20 min on ice with lysis 
buffer (0.5 M NaCl, 50 mM Tris, 1 mM EDTA, 0.05% SDS, 0.5% Triton X- 100, 1 mM PMSF, pH 7.4). Cell 
lysates were centrifuged at 12,000 g for 20 min at 4 °C. Protein concentrations in the supernatants were 
measured using the bicinchoninic acid assay (Pierce, Rockford, IL). Supernatants were electrophoresed 
on 12% SDS-PAGE, and transferred to polyvinylidene diuoride (PVDF) membranes, which were subse-
quently blocked with 5% non-fat milk. Antibodies against the following proteins were used: MMP2/9, 
P-MYPT1 853/MYPT1, P-cofilin/cofilin, P-MLC2/MLC2, ROCK-II, ERα and beta-actin. After the sec-
ondary antibodies were incubated for 1 h, proteins were detected using an enhanced ECL system (GE 
Healthcare, Little Chalfont, Buckinghamshire, UK). Semi-quantifications were performed according to 
densitometric analysis, in conjunction with the Quantity One software package.
Coimmunoprecipitation Assays. HUVEC were harvested in 100 mM Tris-HCl (pH 6.8), 4% sodium 
dodecyl sulfate (SDS), 20% glycerol, 1 mM Na3VO4, 1 mM NaF, and 1 mM phenylmethylsulfonyl fluo-
ride (PMSF). Equal amounts of cell lysates were incubated with 1 μ g precipitating Ab, overnight at 4 °C 
under gentle agitation. 25 μ l of a 1:1 ChIP-Grade Protein G Agarose Bead (Cat. no. 9007 s, Cell Signaling 
Technology) were added, and the samples were rolled at 4 °C for 3 h. The samples were then pelleted, 
washed, and resuspended in 25 μ l 2 × Laemmli buffer for immunoblotting.
Statistical analysis. Each experiment was performed independently at least 3 times. Means ± SD 
were compared using the Student’s t-test according to the following statistical criteria: p < 0.05 = signif-
icant; p < 0.01 = highly significant; p < 0.001 = extremely significant. All relevant data are presented as 
means ± SD.
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